National Institute for Occupational Safety and Health (NIOSH), Safety and Occupational Health Study Section: Notice of Charter Renewal, 45504 [2016-16583]
Download as PDF
<![CDATA[
45504
Federal Register / Vol. 81, No. 135 / Thursday, July 14, 2016 / Notices
iii. Hyaluronic acid (to be assessed for
review in next update)
C. Topical and transdermal agents (to
be assessed for review in next
update)
i. Capsaicin (to be assessed for review
in next update)
ii. NSAIDs (to be assessed for review
in next update)
II. Cell-based therapies
A. Platelet-rich plasma
B. Intraarticular or arthroscopic
administration of mesenchymal
stem-cells or chondrocytes or tissue
C. Exclusions:
i. Phase I or II trials will not be
included for efficacy, as the
interventions are generally not
FDA-approved for use.
III. Physical treatments and/or weight
loss
A. Physical therapy and exercise
programs
i. Manual therapy
ii. Land-based therapy and/or exercise
iii. Exercise programs (aerobic,
resistance)
iv. Aquatherapy
v. Balneotherapy, mud therapy
vi. Heat or cold
vii. Self-management programs
B. Weight loss
C. Braces or kinesiology taping
D. Orthotic shoe inserts and/or
wedges
E. Vibrating platform
F. Neuromuscular electrical
stimulation (e.g., Transcutaneous
electrical nerve stimulation)
IV. Acupuncture (to be assessed for
review in next update)
A. Needle acupuncture alone (to be
assessed for review in next update)
B. Moxibustion (to be assessed for
review in next update)
V. Combination interventions (to be
assessed for review in next update)
A. Sequential treatment algorithms (to
be assessed for review in next
update)
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Comparators
I. Pharmacologic treatments: Placebocontrolled or head-to-head noninferiority only
II. Cell-based therapies: Placebo- or
sham-controlled only
III. Physical treatments and/or weight
loss: Placebo-controlled, usual carecontrolled, or wait list-controlled
only except for weight loss
IV. Neuromuscular electrical
stimulation: Sham stimulation
without current
V. Wait list
VI. Treatment as usual
VII. Studies that use the untreated knee
as a control will be excluded, based
on evidence indicating that
VerDate Sep<11>2014
19:33 Jul 13, 2016
Jkt 238001
individuals with OA in one knee
are likely to have some, but not
necessarily identically, reduced
function in the other knee and that
treatment of one knee only may
improve pain in that knee but may
not markedly improve function
VIII. Studies that use participants as
their own controls will be excluded,
unless no randomized controlled
trials are identified for a particular
intervention of interest, as quasiexperimental designs provide
weaker evidence.
IX. Exclusions:
A. Studies that use an active control
that has not been established to be
effective will be excluded. Efficacy
and effectiveness must be
established before examining
comparative effectiveness
questions.
Outcomes
I. Short-term clinical outcomes
A. Pain (e.g., VAS, WOMAC, KOOS,)
B. Joint stiffness (WOMAC)
C. Function (WOMAC, Lequesne,
others)
D. OARSI physical outcomes (e.g.,
timed up-and-go, 6-minute walk
test)
E. Patient Reported Outcome
Measurement System (PROMIS®)
and Osteoarthritis-Computer
Adaptive Test (OA–CAT)
F. Inflammation or effusion
G. Medication use
II. Long-term clinical outcomes
A. Any of the short-term clinical
outcomes
B. Instrumental activities of daily
living (IADLs)
C. Quality of life (e.g., SF–36,
EuroQuol EQ–5D, Arthritis SelfEfficacy scale, global assessment,
patient satisfaction)
D. Surgery (i.e., rate of undergoing
knee replacement)
III. Adverse effects of intervention(s)
IV. Outcome reporting
A. Only studies that report outcomes
for knee OA alone
B. Mean differences at followup or
percent of responders at followup
will be abstracted
Timing
Minimum 1 month follow-up from
initiation of treatment
Settings
Any setting
Andrew B. Bindman,
AHRQ Director.
[FR Doc. 2016–16632 Filed 7–13–16; 8:45 am]
BILLING CODE 4160–90–P
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health (NIOSH), Safety and
Occupational Health Study Section:
Notice of Charter Renewal
This gives notice under the Federal
Advisory Committee Act (Pub. L. 92–
463) of October 6, 1972, that the Safety
and Occupational Health Study Section,
Centers for Disease Control and
Prevention, Department of Health and
Human Services, has been renewed for
a 2-year period through June 30, 2018.
For more information contact: JoAnne
Fairbanks, Executive Secretary, Safety
and Occupational Health Study Section,
Department of Health and Human
Services, 1600 Clifton Road NE.,
Mailstop E74, Atlanta, Georgia 30333,
telephone 304/285–6143 or fax 304/
285–6147.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2016–16583 Filed 7–13–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
National Institute for Occupational
Safety and Health (NIOSH), Advisory
Board on Radiation and Worker Health
(ABRWH or Advisory Board)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), and pursuant to the
requirements of 42 CFR 83.15(a), the
Centers for Disease Control and
Prevention (CDC), announces the
following meeting of the
aforementioned committee:
Times and Dates: 8:15 a.m.–5:00 p.m.,
Mountain Time, August 9, 2016; 8:15
a.m.–1:00 p.m., Mountain Time, August
10, 2016.
Public Comment Time and Date: 5:00
p.m.–6:00 p.m.*, Mountain Time,
August 9, 2016.
E:\FR\FM\14JYN1.SGM
14JYN1
]]>Agencies
[Federal Register Volume 81, Number 135 (Thursday, July 14, 2016)]
[Notices]
[Page 45504]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-16583]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
National Institute for Occupational Safety and Health (NIOSH),
Safety and Occupational Health Study Section: Notice of Charter Renewal
This gives notice under the Federal Advisory Committee Act (Pub. L.
92-463) of October 6, 1972, that the Safety and Occupational Health
Study Section, Centers for Disease Control and Prevention, Department
of Health and Human Services, has been renewed for a 2-year period
through June 30, 2018.
For more information contact: JoAnne Fairbanks, Executive
Secretary, Safety and Occupational Health Study Section, Department of
Health and Human Services, 1600 Clifton Road NE., Mailstop E74,
Atlanta, Georgia 30333, telephone 304/285-6143 or fax 304/285-6147.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention and the Agency
for Toxic Substances and Disease Registry.
Catherine Ramadei,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2016-16583 Filed 7-13-16; 8:45 am]
BILLING CODE 4163-18-P
